Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.
| Last: | $13.75 |
|---|---|
| Change Percent: | 0.15% |
| Open: | $13.75 |
| Close: | $13.75 |
| High: | $13.76 |
| Low: | $13.75 |
| Volume: | 1,534,573 |
| Last Trade Date Time: | 11/13/2020 04:56:03 pm |
| Market Cap: | $477,469,616 |
|---|---|
| Float: | 30,304,562 |
| Insiders Ownership: | N/A |
| Institutions: | 3 |
| Short Percent: | 6290094% |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.amagpharma.com |
| Country: | US |
| City: | Waltham |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about AMAG Pharmaceuticals Inc. (NASDAQ: AMAG).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
